PREDICTIVE VALUE OF IL28B GENE POLYMORPHISM COMBINED WITH PRETREATMENT SERUM IP-10 QUANTIFICATION FOR RESPONSE TO PEGINTERFERON AND RIBAVIRIN IS ENHANCED IN COMPARISON WITH ANY OF THESE BIOMARKERS ALONE

摘要

The current invention relates to a method of combining IL28B genotype determination with pre-treatment serum level measurement of IP-10 to predict the outcome of a sustained virological response (SVR) or non-response to peginterferon and ribavirin for individual patients infected with HCV.